ASCO GI Conference Coverage

Should Routine Colon Cancer Screening Start at 45, Not 50?

(Medscape Medical News) Feb 18, 2020 - Should the age be lowered in view of the mounting reports of an increase in CRC in younger adults? Experts argued both for and against the move here at the 2020 Gastrointestinal Cancers Symposium.

read article (free registration required)

New Data From ASCO's TAPUR Study to be Presented at 2020 Gastrointestinal Cancers Symposium

(2020 GI Cancers Symposium) Jan 24, 2020 - Positive findings from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study cohorts on the potential benefit of various molecularly targeted drugs in patients with advanced colorectal cancer will be presented at the 2020 Gastrointestinal Cancers Symposium, taking place January 23-25, 2020 at the Moscone West Building in San Francisco, California. The TAPUR Study is the first clinical trial conducted by ASCO and aims to describe the performance (both safety and efficacy) of Food and Drug Administration (FDA)-approved, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic alteration.

read press release

New Drug Combo Potentially Practice Changing in Advanced HCC

(Medscape Medical News) Jan 27, 2020 - For patients with unresectable hepatocellular carcinoma (HCC), the combination of atezolizumab (Tecentriq, Genentech) plus bevacizumab (Avastin, Genentech) has already shown better efficacy than standard treatment with sorafenib (Nexavar, Bayer) in the IMbrave150 trial.

read article (free registration required)

Doublet for BRAF-Mutant Colon Cancer Heads to FDA

(MedPage Today) Jan 25, 2020 - Only the two-drug combination of encorafenib (Braftovi) plus cetuximab (Erbitux) will undergo regulatory review by the FDA for metastatic BRAF-mutant colorectal cancer at this time, a researcher reported here.

read article (free registration required)

No Survival Benefit With Avelumab Maintenance in Gastric Cancer

(MedPage Today) Jan 24, 2020 - So-called switch maintenance with an immune checkpoint inhibitor failed to improve overall survival (OS) in treatment-naive HER2-negative advanced gastric or gastroesophageal junction cancer, results of a phase III trial found.

read article (free registration required)

Primary Tumor Surgery Not Needed in Metastatic CRC

(MedPage Today) Jan 26, 2020 - Resection of the primary tumor ahead of chemotherapy yielded no survival benefit for newly diagnosed metastatic colorectal cancer (CRC) patients with asymptomatic primaries, a randomized trial from Japan found.

read article (free registration required)

No Benefit With Boosted Radiation Dose in Esophageal Cancer

(Medscape Medical News) Jan 24, 2020 - Escalating the dose of radiation therapy does not appear to improve outcomes for patients with esophageal cancer who are receiving definitive chemoradiation, according to new findings.

read article (free registration required)

Taiho Oncology Presents Data On Lonsurf® (Trifluridine And Tipiracil) And Futibatinib (TAS-120) At ASCO 2020 Gastrointestinal Cancers Symposium (ASCO GI)

(Taiho Oncology) Jan 25, 2020 - Taiho Oncology, Inc. announced today the presentation of a pooled analysis for hematologic adverse events of the global Phase III TAGS and RECOURSE trials evaluating LONSURF® (trifluridine and tipiracil) in patients with metastatic colorectal cancer (mCRC) and metastatic gastric or gastroesophageal junction cancer (mGC/GEJC), respectively.

read corporate press release

Onvasertib Demonstrates Effectiveness as Pan-KRAS Inhibitor with Confirmed Tumor Regression and Clinical Benefit Achieved in KRAS-Mutated mCRC Patients

(Yahoo! News) Jan 27, 2020 - All patients showed tumor regression by radiographic scan at 8 weeks and confirmation by further tumor shrinkage at 16 weeks; clinical benefit achieved in 100% (n=5) of patients.

read article

Data From NantHealth’s GPS Cancer Platform Reveals Increased Opportunities For HER2 Directed Therapy in Colorectal Cancer Patients

(Yahoo! Finance) Jan 25, 2020 - NantHealth, Inc. today announced results of a fifty-gene breast cancer RNA subtype classifier applied to 167 colorectal cancer (CRC) patients during a poster session at the 2020 GI.

read article

AVEO Oncology and Biodesix Announce Results from Phase 1b Study of Ficlatuzumab, Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer

(Yahoo! Finance) Jan 27, 2020 - AVEO Oncology and Biodesix, Inc. today announced the presentation of results from an investigator-sponsored Phase 1b trial of ficlatuzumab, AVEO’s potent hepatocyte growth factor (HGF) inhibitory antibody product candidate, in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC).

read article

Bellicum Presents New Translational Data for BPX-601 at ASCO GI Cancers Symposium

(Bellicum) Jan 24, 2020 - Bellicum Pharmaceuticals, Inc. today presented new Phase 1 translational results for BPX-601 at the 2020 GI Cancers Symposium in San Francisco.

read corporate press release

Oncolytics Biotech® Announces Statistically Significant Data Identifying CEACAM6 as a Prospective Prognostic Biomarker for Pelareorep in the Treatment of Pancreatic Adenocarcinoma

(Oncolytics Biotech) Jan 27, 2020 - Over 80% improvement in progression free survival in patients with low levels of CEACAM6.

read corporate press release

SBP Summarizes SBP-101 Phase 1 Clinical Data Presented at ASCO 2020 Annual Gastrointestinal Cancers Symposium

(Sun BioPharma) Jan 24, 2020 - SBP-101 was well tolerated in combination with gemcitabine and nab-paclitaxel. Objective Response Rate (ORR) was 62% by RECIST criteria.

read corporate press release

NuCana Announces First Patients Dosed in Both US and Europe in Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer

(Yahoo! Finance) Jan 27, 2020 - Global NuTide:121 study is enrolling up to 828 patients and comparing acelarin plus cisplatin to gemcitabine plus cisplatin.

read article

Lexicon Pharmaceuticals Announces Real-World Data on Telotristat Ethyl’s Antiproliferative Effects in Patients With Carcinoid Syndrome

(Yahoo! Finance) Jan 24, 2020 - Lexicon Pharmaceuticals, Inc., announced today real-world data on XERMELO’s® (telotristat ethyl) antiproliferative effects in patients with carcinoid syndrome that were presented at the 2020 GI Cancers Symposium.

read article

Leap Therapeutics Presents Updated Data at the ASCO 2020 Gastrointestinal Cancers Symposium (ASCO GI) Global Meeting

(Yahoo! Finance) Jan 23, 2020 - Leap Therapeutics, Inc. today presented updated clinical data from its recently completed Phase 1/2 clinical trial of DKN-01 in patients with advanced or recurrent esophagogastric cancer (EGC) at the 2020 ASCO GI annual meeting.

read article

Blood-Based Test Could Help Identify Hard-to-Detect Gastrointestinal Cancers

(2020 GI Cancers Symposium) Jan 21, 2020 - A blood-based screening test using cell-free DNA to identify methylation signals of hard-to-detect gastrointestinal (GI) cancers that could potentially help detect cancer at earlier stages will be presented 2020 Gastrointestinal Cancers Symposium, taking place January 23-25 in San Francisco, California. “The potential of this test is to diagnose cancer earlier, when it’s more treatable. The ability to do that across cancer types could be quite valuable. Many of the cancer types that this test detects don’t currently have screening tests that allow earlier cancer detection before the cancers cause symptoms,” said lead investigator Brian M. Wolpin, MD, MPH, who is Director of the Gastrointestinal Cancer Center and Director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute in Boston.

read press release

New Drug Combinations Maintain Quality of Life for Patients With Colorectal and Liver Cancers

(2020 GI Cancers Symposium) Jan 21, 2020 - Patient-reported outcomes from two large studies show that quality of life is maintained longer with newer drug combinations compared with standard of care for the treatment of patients with a specific type of colorectal cancer and unresectable hepatocellular carcinoma. The combination of atezolizumab and bevacizumab delayed declines in quality of life in a study comparing the two-drug treatment with sorafenib (the standard of care) for patients with unresectable hepatocellular carcinoma (HCC). Atezolizumab is a programmed cell death ligand 1 (PD-L1) inhibitor; bevacizumab is a vascular endothelial growth factor (VEGF) inhibitor.

read press release

Young Adults With Colorectal Cancer in Low-Income and Low-Education Areas, or Urban Areas, Have Worse Overall Survival and a Higher Risk of Death

(2020 GI Cancers Symposium) Jan 21, 2020 - A retrospective analysis of 26,768 young adults age 40 and under found that those who live in areas with lower income (less than $38,000) and lower education (under 79% high school graduation rate), as well as those who live in urban areas, had worse outcomes and a higher risk of death. The results will be presented at the 2020 Gastrointestinal Cancers Symposium, taking place January 23-25 in San Francisco, California. Each year more than 16,000 people under age 50 are diagnosed with colorectal cancer in the United States, and incidence rates among this population have risen 51% since 1994 with the sharpest increase among those age 20 to 29[1].

read press release
Next Page